Canakinumab with and without pembrolizumab in patients with resectable non-small-cell lung cancer: CANOPY-N study design
Abstract
Canakinumab is a human IgGκ monoclonal antibody, with high affinity and specificity for IL-1β. The Canakinumab Anti-Inflammatory Thrombosis Outcome Study (CANTOS) trial, evaluating canakinumab for cardiovascular disease, provided the first signal of the potential of IL-1β inhibition on lung cancer incidence reduction. Here, we describe the rationale and design for CANOPY-N, a randomized Phase II trial evaluating IL-1β inhibition with or without...
Paper Details
Title
Canakinumab with and without pembrolizumab in patients with resectable non-small-cell lung cancer: CANOPY-N study design
Published Date
Apr 1, 2021
Journal
Volume
17
Issue
12
Pages
1459 - 1472
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History